Pharmacologic treatment of cognition in Alzheimer's dementia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 9674761.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Much of the treatment research and development for Alzheimer's disease (AD) in recent years has been based on the cholinergic hypothesis. Cholinesterase inhibition has been shown to improve the symptoms of mild to moderate AD. Two cholinesterase inhibitors (CIs) are now available and two more may be available shortly. Free radical inhibitors, estrogen, and anti-inflammatory drugs may also delay the onset and slow progression of AD. Combination therapies employing CIs and these other drugs may prove successful in the future.
Medical subject headings
- Alzheimer Disease
- Cholinergic Agents
- Cognition
- Nootropic Agents